Echoes the same move by most of the big pharma companies...BD
Merck CEO Richard Clark told Dow Jones Newswires’ Peter Loftus that the “perfect” deal would be a company with a mid-sized market cap, some products already for sale and a research focus that would complement Merck’s research efforts.But every company in the Big Pharma pack is looking for a magic bullet to cure lackluster growth. So will Merck pay up to beat the rest of the desperate pack? AstraZeneca dropped $15 billion for MedImmune last year. Earlier this month, Takeda Pharmaceutial agreed to fork over about $8.8 billion for Millennium Pharmaceuticals.
0 comments :
Post a Comment